StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Prevymis (letermovir by Quarter

Prevymis (letermovir — CMV prophylaxis) — Worldwide reported growth YoY (%) (%)

QuarterlyAnnual

Merck Prevymis (letermovir: 29.0% in Q2 2026, up 8.0 pts from a year earlier.

Latest, Q2 2026
29.0%
Period ended Jun 30, 2026
Change on a year earlier
+8.0 pts
21.0% in Q2 2025
History
24 quarters
Since Q1 2020
Sources
24
Documents cited below

Where the Q2 2026 figure comes from

“|| Prevymis | 295 | 228 | 29 | 147 | 115 | 28 | 148 | 113 | 31”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 3a / 3b Product Sales.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrevymis (letermovir — CMV prophylaxis) — Worldwide reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 202629.0%+8.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 202528.0%+5.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202528.0%-4.0 ptsForm 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202521.0%-10.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 202519.0%-16.0 ptsForm 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202423.0%-26.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202432.0%-6.0 ptsForm 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 202431.0%-8.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 202435.0%-3.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 202349.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 202338.0%+19.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 202339.0%+28.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 202338.0%+24.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 202219.0%-4.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 202211.0%-36.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 202214.0%-23.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗

Cite this data

StockData. (2026). Merck Prevymis (letermovir (%), quarterly Q1 2020–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-prevymis-ww-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.